Europe Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

Europe breast cancer diagnostics market is projected to register a CAGR of 8.7% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Europe Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Ireland, Rest of Europe) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe breast cancer diagnostics market are:

Increasing breast cancer patients among the women population as well as men

Rise in technological advancement for breast cancer diagnostic

Market Players

The key market players operating in the Europe breast cancer diagnostics market are:

F-Hoffmann La Roche Ltd.

Siemens Healthcare GmbH

NanoString.

Cepheid

BIOMERIEUX

Exact Sciences Corporation

Biocept, Inc.

Abacus ALS

1 INTRODUCTION 48

1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE EUROPE BREAST CANCER DIAGNOSTIC MARKET 48
1.4 CURRENCY AND PRICING 50
1.5 LIMITATIONS 50
1.6 MARKETS COVERED 50

2 MARKET SEGMENTATION 54

2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.6 MULTIVARIATE MODELLING 61
2.7 MARKET END USER COVERAGE GRID 62
2.8 TEST TYPE LIFELINE CURVE 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 65
2.11 SECONDARY SOURCES 66
2.12 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 69

4.1 PESTEL ANALYSIS 70
4.2 PORTER'S 5 FORCES 71

5 EPIDEMIOLOGY 72

6 INDUSTRIAL INSIGHTS 73

7 REGULATORY FRAMEWORK 74

8 MARKET OVERVIEW 76

8.1 DRIVERS 78
- 8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
- 8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
- 8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
- 8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
8.2 RESTRAINTS 80
- 8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
- 8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
8.3 OPPORTUNITIES 81
- 8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
- 8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
- 8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
8.4 CHALLENGES 82
- 8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
- 8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83

9 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84

9.1 OVERVIEW 85
9.2 IMAGING 88
- 9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
  - 9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
  - 9.2.1.2 ANALOG MAMMOGRAPHY 90
  - 9.2.1.3 3D BREAST TOMOSYNTHESIS 90
  - 9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
  - 9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
  - 9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
  - 9.2.1.7 OTHERS 90
- 9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
  - 9.2.2.1 OPTICAL IMAGING 91
  - 9.2.2.2 BREAST ULTRASOUND 91
  - 9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
  - 9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
  - 9.2.2.5 BREAST THERMOGRAPHY 92
- 9.2.3 BIOPSY 92
  - 9.2.3.1 SURGICAL BIOPSY 93
  - 9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
  - 9.2.3.3 CORE NEEDLE BIOPSY 93
  - 9.2.3.4 IMAGE-GUIDED BIOPSY 93
  - 9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
- 9.2.4 GENOMIC TEST 94
  - 9.2.4.1 MOLECULAR TESTING 95
    - 9.2.4.1.1 PD-L1 96
    - 9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
    - 9.2.4.1.3 NTRK GENE FUSIONS 96
    - 9.2.4.1.4 PI3KCA GENE MUTATION 96
  - 9.2.4.2 MAMMAPRINT 96
  - 9.2.4.3 ONCOTYPE DX 96
  - 9.2.4.4 OTHERS 96
9.3 BLOOD TEST 97
9.4 OTHERS 98

10 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99

10.1 OVERVIEW 100
10.2 INVASIVE DUCTAL CARCINOMA 103
10.3 DUCTAL CARCINOMA IN SITU 103
10.4 INFLAMMATORY BREAST CANCER 104
10.5 METASTATIC BREAST CANCER 105

11 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106

11.1 OVERVIEW 107
11.2 HOSPITALS 109
11.3 DIAGNOSTICS CENTERS 110
11.4 CLINICS 111
11.5 RESEARCH & ACADEMIC INSTITUTES 111
11.6 OTHERS 112

12 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114

12.1 OVERVIEW 115
12.2 DIRECT TENDER 118
12.3 RETAIL SALES 118
12.4 OTHERS 119

13 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120

13.1 EUROPE 121
- 13.1.1 GERMANY 130
- 13.1.2 FRANCE 136
- 13.1.3 RUSSIA 142
- 13.1.4 ITALY 148
- 13.1.5 U.K. 154
- 13.1.6 SPAIN 160
- 13.1.7 TURKEY 166
- 13.1.8 NETHERLANDS 172
- 13.1.9 BELGIUM 178
- 13.1.10 SWITZERLAND 184
- 13.1.11 IRELAND 190
- 13.1.12 REST OF EUROPE 196

14 EUROPE BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 197

14.1 COMPANY SHARE ANALYSIS: EUROPE 197

15 SWOT ANALYSIS 198

16 COMPANY PROFILE 199

16.1 HOLOGIC, INC. 199
- 16.1.1 COMPANY SNAPSHOT 199
- 16.1.2 REVENUE ANALYSIS 199
- 16.1.3 COMPANY SHARE ANALYSIS 200
- 16.1.4 PRODUCT PORTFOLIO 200
- 16.1.5 RECENT DEVELOPMENTS 201
16.2 SIEMENS HEALTHCARE GMBH 202
- 16.2.1 COMPANY SNAPSHOT 202
- 16.2.2 REVENUE ANALYSIS 203
- 16.2.3 COMPANY SHARE ANALYSIS 203
- 16.2.4 PRODUCT PORTFOLIO 204
- 16.2.5 RECENT DEVELOPMENTS 204
16.3 F. HOFFMANN- LA ROCHE LTD 205
- 16.3.1 COMPANY SNAPSHOT 205
- 16.3.2 REVENUE ANALYSIS 205
- 16.3.3 COMPANY SHARE ANALYSIS 206
- 16.3.4 PRODUCT PORTFOLIO 206
- 16.3.5 RECENT DEVELOPMENTS 207
16.4 KONINKLIJKE PHILIPS N.V. 208
- 16.4.1 COMPANY SNAPSHOT 208
- 16.4.2 REVENUE ANALYSIS 208
- 16.4.3 COMPANY SHARE ANALYSIS 209
- 16.4.4 PRODUCT PORTFOLIO 209
- 16.4.5 RECENT DEVELOPMENTS 210
16.5 ABBOTT 211
- 16.5.1 COMPANY SNAPSHOT 211
- 16.5.2 REVENUE ANALYSIS 211
- 16.5.3 COMPANY SHARE ANALYSIS 212
- 16.5.4 PRODUCT PORTFOLIO 212
- 16.5.5 RECENT DEVELOPMENTS 212
16.6 ABACUS ALS 213
- 16.6.1 COMPANY SNAPSHOT 213
- 16.6.2 PRODUCT PORTFOLIO 213
- 16.6.3 RECENT DEVELOPMENTS 213
16.7 BD 214
- 16.7.1 COMPANY SNAPSHOT 214
- 16.7.2 REVENUE ANALYSIS 214
- 16.7.3 COMPANY SHARE ANALYSIS 215
- 16.7.4 PRODUCT PORTFOLIO 215
- 16.7.5 RECENT DEVELOPMENTS 215
16.8 BIOCEPT, INC. 216
- 16.8.1 COMPANY SNAPSHOT 216
- 16.8.2 REVENUE ANALYSIS 216
- 16.8.3 PRODUCT PORTFOLIO 217
- 16.8.4 RECENT DEVELOPMENTS 217
16.9 BIOMERIEUX 218
- 16.9.1 COMPANY SNAPSHOT 218
- 16.9.2 REVENUE ANALYSIS 218
- 16.9.3 PRODUCT PORTFOLIO 219
- 16.9.4 RECENT DEVELOPMENTS 219
16.10 BIO-RAD LABORATORIES, INC. 220
- 16.10.1 COMPANY SNAPSHOT 220
- 16.10.2 REVENUE ANALYSIS 220
- 16.10.3 PRODUCT PORTFOLIO 221
- 16.10.4 RECENT DEVELOPMENT 221
16.11 CEPHEID 222
- 16.11.1 COMPANY SNAPSHOT 222
- 16.11.2 REVENUE ANALYSIS 222
- 16.11.3 PRODUCT PORTFOLIO 223
- 16.11.4 RECENT DEVELOPMENT 223
16.12 EXACT SCIENCES CORPORATION 224
- 16.12.1 COMPANY SNAPSHOT 224
- 16.12.2 REVENUE ANALYSIS 224
- 16.12.3 COMPANY SHARE ANALYSIS 225
- 16.12.4 PRODUCT PORTFOLIO 225
- 16.12.5 RECENT DEVELOPMENTS 226
16.13 FUJIFILM CORPORATION 227
- 16.13.1 COMPANY SNAPSHOT 227
- 16.13.2 REVENUE ANALYSIS 227
- 16.13.3 PRODUCT PORTFOLIO 228
- 16.13.4 RECENT DEVELOPMENT 228
16.14 GENERAL ELECTRIC 229
- 16.14.1 COMPANY SNAPSHOT 229
- 16.14.2 REVENUE ANALYSIS 229
- 16.14.3 PRODUCT PORTFOLIO 230
- 16.14.4 RECENT DEVELOPMENTS 230
16.15 ILLUMINA, INC. 231
- 16.15.1 COMPANY SNAPSHOT 231
- 16.15.2 REVENUE ANALYSIS 231
- 16.15.3 PRODUCT PORTFOLIO 232
- 16.15.4 RECENT DEVELOPMENTS 232
16.16 MYRIAD GENETICS, INC. 233
- 16.16.1 COMPANY SNAPSHOT 233
- 16.16.2 REVENUE ANALYSIS 233
- 16.16.3 PRODUCT PORTFOLIO 234
- 16.16.4 RECENT DEVELOPMENT 234
16.17 NANOSTRING. 235
- 16.17.1 COMPANY SNAPSHOT 235
- 16.17.2 REVENUE ANALYSIS 235
- 16.17.3 PRODUCT PORTFOLIO 236
- 16.17.4 RECENT DEVELOPMENT 236
- 16.17.5 RECENT DEVELOPMENT 236
16.18 ONCOSTEM. 237
- 16.18.1 COMPANY SNAPSHOT 237
- 16.18.2 PRODUCT PORTFOLIO 237
- 16.18.3 RECENT DEVELOPMENT 237
16.19 PROVISTA DIAGNOSTICS. 238
- 16.19.1 COMPANY SNAPSHOT 238
- 16.19.2 PRODUCT PORTFOLIO 238
- 16.19.3 RECENT DEVELOPMENT 238
16.20 THERMO FISHER SCIENTIFIC INC. 239
- 16.20.1 COMPANY SNAPSHOT 239
- 16.20.2 REVENUE ANALYSIS 239
- 16.20.3 PRODUCT PORTFOLIO 240
- 16.20.4 RECENT DEVELOPMENT 240

17 QUESTIONNAIRE 241

18 RELATED REPORTS 244

LIST OF TABLES

TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020) 50
TABLE 2 MORTALITY RATE OF BREAST CANCER (2020) 50
TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER 50
TABLE 4 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
TABLE 5 EUROPE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 6 EUROPE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 66
TABLE 7 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 67
TABLE 8 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 67
TABLE 9 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 69
TABLE 10 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 69
TABLE 11 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 12 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 71
TABLE 13 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 71
TABLE 14 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 15 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 73
TABLE 16 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 73
TABLE 17 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 73
TABLE 18 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 74
TABLE 19 EUROPE BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 20 EUROPE OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 21 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 80
TABLE 22 EUROPE INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 23 EUROPE DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 24 EUROPE INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 25 EUROPE METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 26 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 87
TABLE 27 EUROPE HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 28 EUROPE DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 29 EUROPE CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 30 EUROPE RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 31 EUROPE OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 32 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 95
TABLE 33 EUROPE DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 34 EUROPE RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 35 EUROPE OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 36 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 103
TABLE 37 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
TABLE 38 EUROPE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
TABLE 39 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
TABLE 40 EUROPE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 104
TABLE 41 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
TABLE 42 EUROPE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
TABLE 43 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 44 EUROPE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
TABLE 45 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 46 EUROPE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 106
TABLE 47 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
TABLE 48 EUROPE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 106
TABLE 49 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
TABLE 50 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 107
TABLE 51 EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 107
TABLE 52 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 53 GERMANY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 54 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 55 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 109
TABLE 56 GERMANY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 109
TABLE 57 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 109
TABLE 58 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 110
TABLE 59 GERMANY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 110
TABLE 60 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
TABLE 61 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 110
TABLE 62 GERMANY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 111
TABLE 63 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
TABLE 64 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 111
TABLE 65 GERMANY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 111
TABLE 66 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
TABLE 67 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 112
TABLE 68 GERMANY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 112
TABLE 69 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 112
TABLE 70 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 112
TABLE 71 GERMANY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 113
TABLE 72 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 73 FRANCE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 74 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 75 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 115
TABLE 76 FRANCE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 115
TABLE 77 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
TABLE 78 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 116
TABLE 79 FRANCE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 116
TABLE 80 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
TABLE 81 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 116
TABLE 82 FRANCE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 117
TABLE 83 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 117
TABLE 84 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 117
TABLE 85 FRANCE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 117
TABLE 86 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 117
TABLE 87 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 118
TABLE 88 FRANCE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 118
TABLE 89 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
TABLE 90 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 118
TABLE 91 FRANCE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 119
TABLE 92 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
TABLE 93 RUSSIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
TABLE 94 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
TABLE 95 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 121
TABLE 96 RUSSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 121
TABLE 97 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 121
TABLE 98 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 122
TABLE 99 RUSSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 122
TABLE 100 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 122
TABLE 101 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 122
TABLE 102 RUSSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 123
TABLE 103 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 123
TABLE 104 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 123
TABLE 105 RUSSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 123
TABLE 106 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 123
TABLE 107 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 124
TABLE 108 RUSSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 124
TABLE 109 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
TABLE 110 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 124
TABLE 111 RUSSIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 125
TABLE 112 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
TABLE 113 ITALY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
TABLE 114 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
TABLE 115 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 127
TABLE 116 ITALY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 127
TABLE 117 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
TABLE 118 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 128
TABLE 119 ITALY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 128
TABLE 120 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
TABLE 121 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 128
TABLE 122 ITALY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 129
TABLE 123 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 124 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 129
TABLE 125 ITALY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 129
TABLE 126 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 127 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 130
TABLE 128 ITALY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 130
TABLE 129 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
TABLE 130 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
TABLE 131 ITALY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 131
TABLE 132 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132
TABLE 133 U.K. IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132
TABLE 134 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132
TABLE 135 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 133
TABLE 136 U.K. IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 133
TABLE 137 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
TABLE 138 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 134
TABLE 139 U.K. NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 134
TABLE 140 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
TABLE 141 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 134
TABLE 142 U.K. BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 135
TABLE 143 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
TABLE 144 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 135
TABLE 145 U.K. GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 135
TABLE 146 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 135
TABLE 147 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 136
TABLE 148 U.K. MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 136
TABLE 149 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 136
TABLE 150 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 136
TABLE 151 U.K. BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 137
TABLE 152 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
TABLE 153 SPAIN IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
TABLE 154 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
TABLE 155 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 139
TABLE 156 SPAIN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 139
TABLE 157 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
TABLE 158 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 140
TABLE 159 SPAIN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 140
TABLE 160 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
TABLE 161 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 140
TABLE 162 SPAIN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 141
TABLE 163 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
TABLE 164 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 141
TABLE 165 SPAIN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 141
TABLE 166 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
TABLE 167 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 142
TABLE 168 SPAIN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 142
TABLE 169 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
TABLE 170 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 142
TABLE 171 SPAIN BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 143
TABLE 172 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
TABLE 173 TURKEY IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
TABLE 174 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
TABLE 175 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 145
TABLE 176 TURKEY IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 145
TABLE 177 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
TABLE 178 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 146
TABLE 179 TURKEY NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 146
TABLE 180 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
TABLE 181 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 146
TABLE 182 TURKEY BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 147
TABLE 183 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 184 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 147
TABLE 185 TURKEY GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 147
TABLE 186 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 187 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 148
TABLE 188 TURKEY MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 148

TABLE 189 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 148
TABLE 190 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 148
TABLE 191 TURKEY BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 149
TABLE 192 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
TABLE 193 NETHERLANDS IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
TABLE 194 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
TABLE 195 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 151
TABLE 196 NETHERLANDS IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 151
TABLE 197 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
TABLE 198 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 152
TABLE 199 NETHERLANDS NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 152
TABLE 200 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
TABLE 201 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 152
TABLE 202 NETHERLANDS BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 153
TABLE 203 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 153
TABLE 204 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 153
TABLE 205 NETHERLANDS GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 153
TABLE 206 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 153
TABLE 207 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 154
TABLE 208 NETHERLANDS MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 154
TABLE 209 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 154
TABLE 210 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 154
TABLE 211 NETHERLANDS BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 155
TABLE 212 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
TABLE 213 BELGIUM IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
TABLE 214 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
TABLE 215 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 157
TABLE 216 BELGIUM IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 157
TABLE 217 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 157
TABLE 218 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 158
TABLE 219 BELGIUM NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 158
TABLE 220 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
TABLE 221 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 158
TABLE 222 BELGIUM BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 159
TABLE 223 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 224 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 159
TABLE 225 BELGIUM GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 159
TABLE 226 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 227 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 160
TABLE 228 BELGIUM MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 160
TABLE 229 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 160
TABLE 230 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 160
TABLE 231 BELGIUM BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 161
TABLE 232 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 233 SWITZERLAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 234 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 235 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 163
TABLE 236 SWITZERLAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 163
TABLE 237 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
TABLE 238 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 164
TABLE 239 SWITZERLAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 164
TABLE 240 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
TABLE 241 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 164
TABLE 242 SWITZERLAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 165
TABLE 243 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 165
TABLE 244 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 165
TABLE 245 SWITZERLAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 165
TABLE 246 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 165
TABLE 247 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 166
TABLE 248 SWITZERLAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 166
TABLE 249 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 166
TABLE 250 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 166
TABLE 251 SWITZERLAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 167
TABLE 252 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 253 IRELAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 254 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 168
TABLE 255 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 169
TABLE 256 IRELAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 169
TABLE 257 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
TABLE 258 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 170
TABLE 259 IRELAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 170
TABLE 260 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
TABLE 261 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 170
TABLE 262 IRELAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 171
TABLE 263 IRELAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
TABLE 264 IRELAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 171
TABLE 265 IRELAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 171
TABLE 266 IRELAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
TABLE 267 IRELAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 172
TABLE 268 IRELAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 172
TABLE 269 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 172
TABLE 270 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 172
TABLE 271 IRELAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 173
TABLE 272 REST OF EUROPE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 174

LIST OF FIGURES

FIGURE 1 EUROPE BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 31
FIGURE 2 EUROPE BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 34
FIGURE 3 EUROPE BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 35
FIGURE 4 EUROPE BREAST CANCER DIAGNOSTIC MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 36
FIGURE 5 EUROPE BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 36
FIGURE 6 EUROPE BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 37
FIGURE 7 EUROPE BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID 39
FIGURE 8 EUROPE BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 41
FIGURE 9 EUROPE BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 42
FIGURE 10 EUROPE BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 45
FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 46
FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030 46
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE BREAST CANCER DIAGNOSTICS MARKET 54
FIGURE 14 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 62
FIGURE 15 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 63
FIGURE 16 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 63
FIGURE 17 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 64
FIGURE 18 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022 77
FIGURE 19 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION) 78
FIGURE 20 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030) 78
FIGURE 21 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE 79
FIGURE 22 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022 84
FIGURE 23 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 85
FIGURE 24 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 85
FIGURE 25 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 86
FIGURE 26 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 92
FIGURE 27 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 93
FIGURE 28 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 93
FIGURE 29 EUROPE BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 94
FIGURE 30 EUROPE BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 99
FIGURE 31 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 100
FIGURE 32 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 100
FIGURE 33 EUROPE BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 101
FIGURE 34 EUROPE BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 101
FIGURE 35 EUROPE BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 174